论文部分内容阅读
目的:观察康艾注射液联合NP方案治疗非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法:将100例NSCLC患者随机分为对照组和观察组各50例。2组均采用NP方案进行化疗,观察组在对照组治疗基础上加用康艾注射液,比较2组的近期疗效及不良反应。结果:近期临床总有效率观察组为44.0%,对照组为38.0%,2组相比差异无统计学意义(P>0.05);观察组生存质量显著提升,白细胞减少发生率显著降低,组间差异具有统计学意义(P<0.05)。结论:康艾注射液在NSCLC化疗过程中具有增效减毒、改善生存质量的作用。
Objective: To observe the clinical efficacy and adverse reactions of Kangai injection combined with NP regimen in the treatment of non-small cell lung cancer (NSCLC). Methods: 100 patients with NSCLC were randomly divided into control group and observation group of 50 cases. Two groups were treated with NP chemotherapy, the observation group in the control group based on the treatment with Kang Ai injection, the two groups were compared the short-term efficacy and adverse reactions. Results: The total clinical effective rate in the observation group was 44.0% and that in the control group was 38.0%. There was no significant difference between the two groups (P> 0.05). The quality of life in the observation group was significantly improved and the incidence of leukopenia was significantly decreased. The difference was statistically significant (P <0.05). Conclusion: Kangai injection has the effect of reducing toxicity and improving quality of life in NSCLC chemotherapy.